恩度联合复方苦参注射液治疗晚期非小细胞肺癌恶性胸腔积液的效果

Abstract
Figure/Table
References (20)
Related Citation (5)

Download: PDF (320 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the efficacy and adverse reactions of recombinant human endostatin (Endostar) combined with compound Kushen Injection in the treatment of advanced non-small cell lung cancer (NSCLC) malignant pleural effusion. Methods Sixty-eight cases of advanced NSCLC patients with malignant pleural effusion from June 2015 to June 2017 in People's Hospital of Wuhan University were randomly divided into treatment group and control group, with 34 patients in each group. In the control group, 30 mg of Endostar was injected into the thoracic cavity and repeated once a week later. On the basis of this, the treatment group was diluted 20 mL of compound Kushen Injection with 250 mL of Sodium Chloride Injection and intravenously instilled once a day, 14 days was used as a course of the treatment. After one month of treatment, the clinical efficacy and adverse reactions were observed. Results The objective remission rate and disease control rate in the treatment group were significantly higher than the control group, the differences were statistically significant (P ＜ 0.05). Adverse reactions of the two groups were mainly nausea, vomiting, fatigue and myelosuppression. The main adverse reactions were grade Ⅰ to Ⅱ, the differences were not statistically significant (P ＞ 0.05). Conclusion The efficacy of Endostar combined with compound Kushen Injection in the treatment of advanced NSCLC malignant pleural effusion was significant, and little adverse reactions, with a relatively positive clinical value.

Key words： Endostar Compound Kushen injection Non-small cell lung cancer Malignant pleural effusion

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SONG Junjun GE Wei▲

Cite this article:

SONG Junjun GE Wei▲. The efficacy of Endostar combined with compound Kushen Injection in the treatment of advanced non-small cell lung cancer malignant pleural effusion[J]. 中国医药导报, 2018, 15(11): 143-146.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I11/143

[1] Porcel JM，Aureli E，Manuel V，et al. Etiology of pleural effusions：analysis of more than 3，000 consecutive thoracenteses [J]. Arch Bronconeumol，2014，50（5）：161-165.
[2] Segal A，Sterrett GF，Frost FA，et al. A diagnosis of malignant pleural mesothelioma can be made by effusion cytology： results of a 20 year audit [J]. Pathol，2013，45（1）：44-48.
[3] Call S，Sánchez D，Ramiporta R. Diagnosis and Treatment of Malignant Pleural Effusion [J]. Malignant Effusions，2012：23-55.
[4] Chen Y，Liang B，Zhao YJ，et al. Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer [J]. Diagn Cytopathol，2012，40（4）：287-291.
[5] Ferician O，Cimpean AM，Avram S，et al. Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane [J]. Anticancer Res，2015，35（12）：6521-6528.
[6] Dresler CM，Olak J，Herndon JE，et al. Phase Ⅲ intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion [J]. Chest，2015，127（3）：909-915.
[7] Pratesi V，La CC，Bartolozzi G. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the National Cancer Institute-sponsored clin?鄄ical trials networks [J]. J Clin Oncol，2007，25（32）：5070-5077.
[8] Heffner JE，Nietert PJ，Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions [J]. Chest，2000，117（1）：79-86.
[9] Cusumano G，Margaritora S，Porziella V，et al. Malignant pleural effusion [J]. Annali Italiani Di Chirurgia，2007，78（5）：389-391.
[10] Grove CS，Lee YC. Vascular endothelial growth factor：the key mediator in pleural effusion formation [J]. Curr Opin Pulm Med，2002，8（4）：294-301.
[11] Yano S，Herbst RS，Shinohara H，et al. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation [J]. Clin Cancer Res，2000，6（3）：957-965.
[12] Matsumori Y，Yano S，Goto H，et al. ZD6474，an inhibitor of vascular endothelial growth factor receptor tyrosine kinase，inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model [J]. Oncol Res，2006，16（1）：15-26.
[13] Ferician O，Cimpean AM，Avram S，et al. Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane [J]. Anticancer Res，2015，35（12）：6521-6528.
[14] Li ZN，Yuan ZF，Mu GY，et al. Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits [J]. Exp Ther Med，2015，10（3）：889-894.
[15] Zhang D，Wu J，Liu S，et al. Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer [J]. Medicine，2017， 96（21）：e7005.
[16] 林洪生.恶性肿瘤中医诊疗指南[M].北京：人民卫生出版社，2014：21-24.
[18] 张伯礼.中药注射剂临床合理使用手册[M].武汉：中国中医药出版社，2016：32-35.
[19] 张敬伟，段冬梅，任中海. 复方苦参注射液与顺铂腹腔灌注化疗联合治疗胃癌恶性腹水[J].中国实验方剂学杂志，2016（11）：179-183.
[20] 刘玲，钟世寿，李国苗. 复方苦参注射液联合顺铂治疗恶性胸腔积液疗效及不良反应观察[J].现代肿瘤医学，2017，25（2）：230-233.